ΒΆ IBD
ΒΆ Definition
Inflammatory bowel disease (IBD) is a group of chronic, relapsing-remitting inflammatory conditions affecting the gastrointestinal tract, primarily comprising Crohn's disease (CD β any GI location, transmural inflammation) and ulcerative colitis (UC β colon only, mucosal inflammation). IBD represents a failure of immune tolerance to commensal microbiota, characterized by barrier dysfunction, gut dysbiosis (particularly sulfate-reducing bacteria overgrowth), pathogenic Th1/Th17 dominance, and bidirectional gut-brain axis disruption where psychological stress directly exacerbates mucosal inflammation through neuroimmune signaling.
ΒΆ Picture It
Think of the gut lining as a gated community where residents (commensal bacteria) live peacefully alongside security guards (immune cells). In IBD, the security system goes haywire in two ways. First, the gates (tight junctions) develop gaps, allowing residents to wander into restricted areas where they trigger alarm responses. Second, the security training program breaks down β instead of learning to recognize residents as friendly, new guards (dendritic cells) are trained to treat everyone as intruders. This creates a permanent state of martial law with constant patrols (inflammatory cells) and structural damage to the neighborhood (ulceration).
Now add a particularly problematic group of squatters: sulfate-reducing bacteria like Desulfovibrio. These bacteria are like illegal chemical factories that moved into abandoned lots β they produce toxic hydrogen sulfide gas (HβS) that corrodes the very walls of the houses (epithelial cells), creating more gaps for other residents to escape through. The more gaps appear, the more alarms sound, the more guards arrive, and the more chemical factories proliferate in the chaos. The brain (management office) keeps getting distress signals and sending down stress hormones that increase water flow (diarrhea) and speed up patrols (motility), which only makes the structural damage worse. The entire system is stuck in a self-perpetuating cycle where the protective response has become the problem.
ΒΆ Mechanism
IBD pathogenesis involves multiple converging pathways creating a self-amplifying inflammatory cycle:
Barrier Breakdown Cascade:
Genetic susceptibility (NOD2, ATG16L1, IL-23R variants) + environmental triggers (NSAIDs, antibiotics, western diet) β disruption of tight junctions (decreased ZO-1, occludin) β increased intestinal permeability β bacterial translocation across epithelium β activation of lamina propria immune cells β release of TNF-Ξ±, IL-1Ξ², IFN-Ξ³ β further tight junction disruption (positive feedback loop)
Loss of Immune Tolerance:
Under normal conditions: dendritic cells sample luminal antigens β migrate to mesenteric lymph nodes β present antigens with IL-10 and TGF-Ξ² β induce Treg differentiation β immune tolerance to commensals
In IBD: inflammatory context changes dendritic cell programming β dendritic cells present antigens with IL-12 and IL-23 β drive Th1 (producing IFN-Ξ³) and Th17 (producing IL-17A, IL-17F, IL-22) differentiation β Treg function suppressed by inflammatory cytokines β loss of tolerance β chronic adaptive immune activation
Sulfate-Reducing Bacteria Amplification:
Inflammation-induced hypoxia β increased sulfate availability in lumen β overgrowth of sulfate-reducing bacteria (particularly Desulfovibrio) β production of HβS β direct epithelial cytotoxicity (inhibits cytochrome c oxidase, disrupts butyrate metabolism) β impaired barrier repair β increased permeability β more inflammation (vicious cycle)
The SRB population in UC can increase 100-1000 fold compared to healthy controls, with HβS concentrations reaching toxic levels (>1 mM in severe UC vs <0.1 mM in health).
Neuroimmune Specification:
Dense TLR expression on gut sensory neurons (particularly TRPV1-positive nociceptors) β bacterial products (LPS, flagellin, peptidoglycan) directly activate sensory neurons β release of CGRP and substance P β modulation of immune cell function β specification of immune response type based on sensory input
This means the immune system requires neurological context to determine appropriate response intensity β in IBD, chronic activation creates hyperresponsive sensory circuits.
Stress-Inflammation Amplification:
Psychological stress β CRH release β activation of mast cells β histamine and tryptase release β increased intestinal permeability β bacterial translocation β IL-6, TNF-Ξ± production β vagal afferent activation β brain receives inflammatory signals β further stress axis activation
Stress also increases colonic motility via CRH-R2 receptors on enteric neurons and increases secretion via prostaglandin pathways, contributing to diarrhea independent of mucosal damage.
ΒΆ Clinical Significance
IBD is a prototypical selfish immune system disorder where the immune response designed to protect barrier integrity becomes the primary driver of tissue destruction. It exemplifies how the failure of immune tolerance creates chronic disease through positive feedback loops.
cPNI Integration β Multi-System Dysfunction:
This condition demonstrates that you cannot treat IBD by addressing only one system. The selfish immune system is responding to real signals: barrier damage, bacterial translocation, and neurological threat specification. Suppressing inflammation (immunosuppressants, biologics like infliximab targeting TNF-Ξ±) without addressing barrier repair, dysbiosis, and stress axes leads to treatment resistance and relapse.
Clinical Thresholds & Biomarkers:
- Fecal calprotectin >250 Β΅g/g indicates active inflammation (normal <50 Β΅g/g)
- CRP >10 mg/L suggests systemic inflammatory activity
- Fecal HβS levels correlate with SRB overgrowth (not routinely measured but research marker)
- Serum albumin
.5 g/dL indicates malabsorption and inflammatory burden
Evolutionary Mismatch Context:
The dramatic rise in IBD in industrialized nations (incidence doubled in last 30 years) reflects multiple mismatches: antibiotic disruption of microbiome development (old friends mechanism), ultra-processed diet depleting short-chain fatty acids (particularly butyrate), chronic stress axis activation without resolution, and environmental toxins (emulsifiers, microplastics) directly damaging barrier integrity.
Intervention Implications:
-
Barrier Repair Protocol:
- Glutamine 5-15g/day (enterocyte fuel and tight junction maintenance)
- Zinc carnosine 75-150mg BID (direct mucosal healing)
- Vitamin D to target 50-80 ng/mL (upregulates antimicrobial peptides, supports Treg function)
- Collagen peptides (provides glycine, proline for tissue repair)
-
Microbiome Correction:
- Target SRBs: molybdenum (inhibits sulfite reductase), bismuth subsalicylate
- Support butyrate producers: resistant starch, Faecalibacterium prausnitzii supplementation
- Restore diversity: fecal microbiota transplantation shows promise in UC
-
Inflammation Resolution:
-
Neuro-Immune Axis Modulation:
- Vagus nerve stimulation protocols
- Stress management (HPA axis dysregulation perpetuates disease)
- Sleep optimization (circadian disruption worsens barrier function)
-
Dietary Intervention:
- Remove processed emulsifiers (carboxymethylcellulose, polysorbate-80)
- Low-FODMAP during flares (reduces fermentable substrate for SRBs)
- Increase polyphenols (support eubiosis and barrier function)
Patient Populations:
Most relevant for autoimmune conditions (rheumatoid arthritis, psoriasis, multiple sclerosis), metabolic disorders (IBD doubles risk of Type 2 Diabetes), and mental health conditions (50-60% of IBD patients have comorbid anxiety/depression driven by chronic inflammation and cytokine effects on brain).
The dense TLR expression on sensory neurons means every IBD patient experiences neurologically-specified immune responses β their nervous system is actively participating in defining the inflammatory program, making psychological and sensory interventions mechanistically relevant, not just supportive.
ΒΆ Key Facts
- Crohn's disease can affect any part of GI tract from mouth to anus; ulcerative colitis limited to colon and rectum
- Transmural inflammation in Crohn's (all layers) vs mucosal/submucosal in UC creates different complication patterns
- Sulfate-reducing bacteria increase 100-1000 fold in UC, with Desulfovibrio the dominant genus
- HβS produced by SRBs reaches >1 mM in severe disease (vs <0.1 mM in health), directly toxic to colonocytes
- Loss of butyrate-producing bacteria (Faecalibacterium, Roseburia) correlates with disease severity β butyrate is primary fuel for colonocytes
- Pathogenic Th1 cells produce IFN-Ξ³ which activates macrophages and inhibits epithelial proliferation
- Pathogenic Th17 cells produce IL-17A/F which recruits neutrophils and perpetuates chronic inflammation
- TLR2, TLR4, TLR5, and TLR9 are densely expressed on gut nociceptive neurons, allowing direct bacterial pattern sensing
- Psychological stress increases colonic permeability within 2 hours via CRH-mast cell axis
- Anti-TNF biologics (infliximab, adalimumab) achieve remission in only 30-40% of patients, highlighting need for multi-system approach
- IBD patients have 2-3x higher risk of depression and anxiety, driven by cytokine effects on brain and gut-brain axis disruption
- Fecal calprotectin >250 Β΅g/g predicts relapse with 90% sensitivity in UC
ΒΆ Connections
- Crohn's disease β IBD subtype with transmural inflammation affecting any GI location, creates fistulas and strictures
- ulcerative colitis β IBD subtype limited to colon with continuous mucosal inflammation from rectum proximally
- sulfate-reducing bacteria β dramatically elevated in IBD, convert sulfate to toxic HβS damaging epithelium
- Desulfovibrio β dominant SRB genus in UC, produces hydrogen sulfide that inhibits butyrate oxidation
- HβS β toxic gas produced by SRBs, damages mitochondria and disrupts epithelial energy metabolism
- intestinal permeability β barrier dysfunction is both cause and consequence of IBD inflammation
- gut dysbiosis β loss of diversity with SRB overgrowth and depletion of butyrate producers drives pathology
- immune tolerance β central failure in IBD where immune system loses ability to tolerate commensal bacteria
- Th1 β pathogenic subset producing IFN-Ξ³, drives macrophage activation and epithelial damage in IBD
- Th17 β pathogenic subset producing IL-17, recruits neutrophils and perpetuates chronic inflammation
- Treg β regulatory T cells suppressed in IBD, losing control over effector T cell responses
- dendritic cells β antigen-presenting cells that present commensals in inflammatory context, driving loss of tolerance
- IL-12 β pro-inflammatory cytokine that drives Th1 differentiation and IFN-Ξ³ production in IBD
- IL-23 β key cytokine driving pathogenic Th17 cells and IL-17 production in IBD pathology
- TNF-Ξ± β master pro-inflammatory cytokine in IBD, therapeutic target for biologics
- IFN-Ξ³ β Th1 cytokine that activates macrophages and inhibits epithelial repair in IBD
- psychological stress β exacerbates IBD via CRH-mast cell axis, increasing permeability and motility
- TLR β toll-like receptors densely expressed on gut sensory neurons, specify immune responses based on bacterial patterns
- gut-brain axis β bidirectional communication disrupted in IBD, with inflammation affecting brain and stress affecting gut
- autoimmune disease β IBD classified as autoimmune with loss of self-tolerance to gut antigens
- butyrate β short-chain fatty acid depleted in IBD, primary fuel for colonocytes and anti-inflammatory mediator
- tight junctions β barrier structures disrupted in IBD allowing bacterial translocation
- mast cells β activated by stress (CRH) and bacteria, release mediators increasing permeability
- substance P β neuropeptide released by sensory neurons, modulates immune cell function in gut
- CGRP β neuropeptide co-released with substance P, regulates immune responses and barrier integrity
- SPMs β specialized pro-resolving mediators depleted in IBD, necessary for inflammation resolution
- Omega-3 fatty acids β substrate for SPM synthesis, therapeutic intervention in IBD
- fecal microbiota transplantation β intervention showing efficacy in UC by restoring microbial diversity
- calprotectin β neutrophil protein marker in stool, indicates active intestinal inflammation
- CRP β systemic inflammation marker elevated in active IBD
- vitamin D β immunomodulator supporting Treg function and antimicrobial peptide production
- NF-ΞΊB β master transcription factor driving inflammatory cytokine production in IBD
ΒΆ Module References
- Module 1 β Immunoception and interoception (TLR on sensory neurons specifying immune responses)
- Module 3 β Neuroendocrinology (stress axis activation via CRH-mast cell pathway)
- Module 5 β Organs I (gut barrier, microbiome, neuro-immune integration)
- Module 6 β Wound healing and chronic disease mechanisms